Manning Paul B
CIK 0001494695 Name as filed on the most recent filing
Filed as Manning Paul B (44)
89 transaction lines · from 44 filings · filed 2016-09-15 to 2026-06-08 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Liquidia Corp 6 filings
- ISSUER Candel Therapeutics, Inc. 4 filings
- ISSUER Verrica Pharmaceuticals Inc. 15 filings
- ISSUER Taysha Gene Therapies, Inc. 9 filings
- ISSUER Acumen Pharmaceuticals, Inc. 1 filings
- ISSUER Dova Pharmaceuticals Inc. 8 filings
- ISSUER AveXis, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
82 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-04 |
Liquidia Corp LQDA |
S, Open-market sale | 88,487 disposed | 64.28 | 5,687,944.36 | Form 4, filing 0001494695-26-000011 | |
| 2026-06-04 |
Liquidia Corp LQDA |
S, Open-market sale | 68,265 disposed | 63.83 | 4,357,354.95 | Form 4, filing 0001494695-26-000011 | |
| 2026-06-04 |
Liquidia Corp LQDA |
S, Open-market sale | 19,125 disposed | 62.62 | 1,197,607.50 | Form 4, filing 0001494695-26-000011 | |
| 2026-06-04 |
Liquidia Corp LQDA |
S, Open-market sale | 12,610 disposed | 64.42 | 812,336.20 | Form 4, filing 0001494695-26-000011 | |
| 2026-06-04 |
Liquidia Corp LQDA |
S, Open-market sale | 11,513 disposed | 63.13 | 726,815.69 | Form 4, filing 0001494695-26-000011 | |
| 2026-02-23 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 550,458 acquired | 5.45 | 2,999,996.10 | Form 4, filing 0001193125-26-078246 | |
| 2025-11-25 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 2,750,762 acquired | 4.24 | 11,670,107.78 | Form 4, filing 0001494695-25-000004 | |
| 2025-11-25 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 1,375,380 acquired | 4.24 | 5,835,049.65 | Form 4, filing 0001494695-25-000004 | |
| 2025-09-02 |
Liquidia Corp LQDA |
S, Open-market sale | 254,038 disposed | 28.67 | 7,283,269.46 | Form 4, filing 0001415889-25-023468 | |
| 2025-09-02 |
Liquidia Corp LQDA |
S, Open-market sale | 74,230 disposed | 29.14 | 2,163,062.20 | Form 4, filing 0001415889-25-023468 | |
| 2025-08-29 |
Liquidia Corp LQDA |
S, Open-market sale | 188,232 disposed | 27.62 | 5,198,967.84 | Form 4, filing 0001415889-25-023468 | |
| 2025-08-28 |
Liquidia Corp LQDA |
S, Open-market sale | 154,337 disposed | 27.94 | 4,312,175.78 | Form 4, filing 0001415889-25-023468 | |
| 2025-05-30 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 750,000 acquired | 2.75 | 2,062,500.00 | Form 4, filing 0001415889-25-015480 | |
| 2024-12-16 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 750,000 acquired | 6.00 | 4,500,000.00 | Form 4, filing 0000950170-24-137889 | |
| 2024-12-16 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 500,000 acquired | 6.00 | 3,000,000.00 | Form 4, filing 0000950170-24-137889 | |
| 2024-11-22 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 18,426,966 acquired | Not reported | Not priced | Form 4, filing 0001415889-24-027709 | |
| 2024-11-22 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 4,494,382 acquired | Not reported | Not priced | Form 4, filing 0001415889-24-027709 | |
| 2024-09-12 |
Liquidia Corp LQDA |
P, Open-market purchase | 337,078 acquired | 8.90 | 2,999,994.20 | Form 4, filing 0001104659-24-100179 | |
| 2024-06-27 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 1,333,333 acquired | 2.25 | 2,999,999.25 | Form 4, filing 0001415889-24-018515 | |
| 2023-12-14 |
Liquidia Corp LQDA |
P, Open-market purchase | 279,330 acquired | 7.16 | 2,000,002.80 | Form 4, filing 0001104659-23-126932 | |
| 2023-11-17 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 100,000 acquired | 1.63 | 163,000.00 | Form 4, filing 0001209191-23-055942 | |
| 2023-08-16 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 16,466,667 acquired | 0.90 | 14,820,000.30 | Form 4, filing 0001209191-23-046154 | |
| 2023-07-24 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 200,000 acquired | 5.02 | 1,004,000.00 | Form 4, filing 0001209191-23-043255 | |
| 2022-10-31 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 1,500,000 acquired | 2.00 | 3,000,000.00 | Form 4, filing 0001209191-22-055263 | |
| 2022-07-05 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 4,761,904 acquired | 2.10 | 9,999,998.40 | Form 4, filing 0001209191-22-040581 | |
| 2022-04-18 |
Liquidia Corp LQDA |
P, Open-market purchase | 392,156 acquired | 5.10 | 1,999,995.60 | Form 4, filing 0001104659-22-047360 | |
| 2022-02-03 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 50,000 acquired | 7.84 | 392,000.00 | Form 4, filing 0001209191-22-007126 | |
| 2022-02-03 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 26,602 acquired | 7.84 | 208,559.68 | Form 4, filing 0001209191-22-007126 | |
| 2022-02-02 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 58,000 acquired | 7.77 | 450,660.00 | Form 4, filing 0001209191-22-007126 | |
| 2022-02-02 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 45,000 acquired | 7.77 | 349,650.00 | Form 4, filing 0001209191-22-007126 | |
| 2022-02-02 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 22,000 acquired | 7.77 | 170,940.00 | Form 4, filing 0001209191-22-007126 | |
| 2021-12-03 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 19,977 acquired | 9.22 | 184,187.94 | Form 4, filing 0001209191-21-068031 | |
| 2021-12-02 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 30,023 acquired | 9.45 | 283,717.35 | Form 4, filing 0001209191-21-068031 | |
| 2021-11-24 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 2,202 acquired | 13.19 | 29,044.38 | Form 4, filing 0001209191-21-067005 | |
| 2021-11-23 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 20,000 acquired | 12.54 | 250,800.00 | Form 4, filing 0001209191-21-066702 | |
| 2021-07-29 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 1,625,000 acquired | 8.00 | 13,000,000.00 | Form 4, filing 0000899243-21-031614 | |
| 2021-07-29 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 20,000 acquired | 7.30 | 145,944.00 | Form 4, filing 0000899243-21-030774 | |
| 2021-07-27 |
Candel Therapeutics, Inc. CADL |
P, Open-market purchase | 36,000 acquired | 7.36 | 264,834.00 | Form 4, filing 0000899243-21-030774 | |
| 2021-07-06 |
Acumen Pharmaceuticals, Inc. ABOS |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0001209191-21-046042 | |
| 2021-05-14 |
Taysha Gene Therapies, Inc. TSHA |
P, Open-market purchase | 12,000 acquired | 20.98 | 251,760.00 | Form 4, filing 0001209191-21-033009 | |
| 2021-04-13 |
Liquidia Corp LQDA |
P, Open-market purchase | 198,413 acquired | 2.52 | 500,000.76 | Form 4, filing 0001104659-21-050550 | |
| 2021-03-25 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 739,830 acquired | 14.75 | 10,912,492.50 | Form 4, filing 0001209191-21-023388 | |
| 2020-08-20 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 20,000 acquired | 9.09 | 181,800.00 | Form 4, filing 0001209191-20-047865 | |
| 2020-08-18 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 10,000 acquired | 8.55 | 85,500.00 | Form 4, filing 0001209191-20-047409 | |
| 2020-08-17 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 6,000 acquired | 6.92 | 41,520.00 | Form 4, filing 0001209191-20-047100 | |
| 2020-08-14 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 50,000 acquired | 6.51 | 325,500.00 | Form 4, filing 0001209191-20-046880 | |
| 2020-08-13 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 108,500 acquired | 6.41 | 695,485.00 | Form 4, filing 0001209191-20-046880 | |
| 2019-10-10 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 6,900 acquired | 15.05 | 103,845.00 | Form 4, filing 0001209191-19-052936 | |
| 2019-10-09 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 8,778 acquired | 14.06 | 123,418.68 | Form 4, filing 0001209191-19-052936 | |
| 2019-10-08 |
Verrica Pharmaceuticals Inc. VRCA |
P, Open-market purchase | 5,208 acquired | 14.02 | 73,016.16 | Form 4, filing 0001209191-19-052936 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 72
- Open-market sale 10
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Manning Paul B, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001494695
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6